21 August 2017

PDMR Dealing

LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 122.5 pence per Ordinary Share.  Following the acquisition, Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary Shares, representing 0.12% of the Company’s issued share capital.

The notification of dealing form can be found below.

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
   
N+1 Singer (Nominated Adviser and UK Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / James White  
   
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway /  Natalie Garland-Collins veronapharma@fticonsulting.com
   
ICR, Inc. (US Media and Investor enquiries)  
Darcie Robinson Tel: +1 203-682-8379
Darcie.Robinson@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


1 Details of the person discharging managerial responsibilities/person closely associated
a) Name David Ebsworth
2 Reason for the notification
a) Position/status Non-Executive Chairman
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
b) LEI 213800EVI6O6J3TIAL06
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 5 pence each
Identification code GB00BYW2KH80
b) Nature of the transaction David Ebsworth purchased 8,130 Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
122.5 pence per Ordinary Share 8,130 Ordinary Shares
 
d) Aggregated information N/A
-  Aggregated volume
-  Price
 
e) Date of the transaction 17 August 2017
f) Place of the transaction London Stock Exchange, AIM


Primary Logo

Verona Pharma plc

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

 

 

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 950 9144
verona@optimumcomms.com

Argot Partners (Investor enquiries)
Stephanie Marks
Tel. +1 646 644 9590
verona@argotpartners.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us